Abuse liability profile of three substituted tryptamines

Journal of Pharmacology and Experimental Therapeutics

Volumn 338, Issue 1, 2011, Pages 280-289

  Gatch, Michael B ^a   Forster, Michael J ^a   Janowsky, Aaron ^b   Eshleman, Amy J ^b  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,5 DIMETHOXY 4 METHYLAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 5 METHOXY ALPHA METHYLTRYPTAMINE; 5 N,N DIETHYL 5 METHOXYTRYPTAMINE; CARRIER PROTEIN; COCAINE; LYSERGIDE; METHAMPHETAMINE; MONOAMINE TRANSPORTER; N,N DIISOPROPYLTRYPTAMINE; N,N DIMETHYLTRYPTAMINE; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER; TRYPTAMINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CHEMICAL ANALYSIS; CHEMICAL MODIFICATION; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DRUG ABUSE; DRUG POTENCY; HALLUCINATION; INHIBITION KINETICS; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RAT; SEROTONIN RELEASE; SIGNAL TRANSDUCTION; STIMULUS RESPONSE; TOXICITY TESTING;

ANIMALS; DISCRIMINATION LEARNING; HALLUCINOGENS; HEK293 CELLS; HUMANS; MALE; MICE; MOTOR ACTIVITY; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN; SUBSTANCE-RELATED DISORDERS; TRYPTAMINES;

EID: 79959528477     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.179705     Document Type: Article

References (26)

1. Adkins EM, Barker EL, and Blakely RD (2001) Interactions of tryptamine derivatives with serotonin transporter species variants implicate transmembrane domain I in substrate recognition. Mol Pharmacol 59:514-523. (Pubitemid 32179931)
2. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
3. Cozzi NV, Gopalakrishnan A, Anderson LL, Feih JT, Shulgin AT, Daley PF, and Ruoho AE (2009) Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter. J Neural Transm 116:1591-1599.
4. Deneau G, Yanagita T, and Seevers MH (1969) Self-administration of psychoactive substances by the monkey. Psychopharmacologia 16:30-48.
5. Eshleman AJ, Carmolli M, Cumbay M, Martens CR, Neve KA, and Janowsky A (1999) Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type. J Pharmacol Exp Ther 289:877-885. (Pubitemid 29191245)
6. Fantegrossi WE, Murnane KS, and Reissig CJ (2008) The behavioral pharmacology of hallucinogens. Biochem Pharmacol 75:17-33. (Pubitemid 350235393)
7. Fiorella D, Rabin RA, and Winter JC (1995) The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs. I: Antagonist correlation analysis. Psychopharmacology 121:347-356.
8. Gable RS (2007) Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids. Addiction 102:24-34.
9. Gatch MB, Rutledge MA, Carbonaro T, and Forster MJ (2009) Comparison of the discriminative stimulus effects of dimethyltryptamine with different classes of psychoactive compounds in rats. Psychopharmacology 204:715-724.
10. Glennon RA (1999) Arylalkylamine drugs of abuse: an overview of drug discrimination studies. Pharmacol Biochem Behav 64:251-256.
11. Glennon RA, Chaurasia C, and Titeler M (1990) Binding of indolylalkylamines at 5-HT2 serotonin receptors: examination of a hydrophobic binding region. J Med Chem 33:2777-2784. (Pubitemid 20312143)
12. Glennon RA, Jacyno JM, and Young R (1983) A comparison of the behavioral properties of (+)-, (-)-, and (+)- 5-methoxy-alpha-methyltryptamine. Biol Psychiatry 18:493-498.
13. Halpern JH (2004) Hallucinogens and dissociative agents naturally growing in the United States. Pharmacol Ther 102:131-138.
14. Knight AR, Misra A, Quirk K, Benwell K, Revell D, Kennett G, and Bickerdike M (2004) Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol 370:114-123. (Pubitemid 39222863)
15. Kurrasch-Orbaugh DM, Watts VJ, Barker EL, and Nichols DE (2003) Serotonin 5-hydroxytryptamine 2A receptor-coupled phospholipase C and phospholipase A2 signaling pathways have different receptor reserves. J Pharmacol Exp Ther 304: 229-237. (Pubitemid 36008933)
16. Lyon RA, Titeler M, Seggel MR, and Glennon RA (1988) Indolealkylamine analogs share 5-HT2 binding characteristics with phenylalkylamine hallucinogens. Eur J Pharmacol 145:291-297. (Pubitemid 18018849)
17. May JA, McLaughlin MA, Sharif NA, Hellberg MR, and Dean TR (2003) Evaluation of the ocular hypotensive response of serotonin 5-HT1A and 5-HT2 receptor ligands in conscious ocular hypertensive cynomolgus monkeys. J Pharmacol Exp Ther 306:301-309. (Pubitemid 36734385)
18. McCambridge J, Winstock A, Hunt N, and Mitcheson L (2007) 5-Year trends in use of hallucinogens and other adjunct drugs among UK dance drug users. Eur Addict Res 13:57-64. (Pubitemid 44973727)
19. McKenna DJ (2004) Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges. Pharmacol Ther 102:111-129.
20. Nagai F, Nonaka R, and Satoh Hisashi Kamimura K (2007) The effects of nonmedically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur J Pharmacol 559:132-137. (Pubitemid 46295399)
21. National Research Council (2003) Guidelines for the Care and Use of Mammals in Neuroscience and Behavioral Research. The National Academies Press, Washington, DC.
22. Newman-Tancredi A, Gavaudan S, Conte C, Chaput C, Touzard M, Verrièle L, Audinot V, and Millan MJ (1998) Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPγS binding study. Eur J Pharmacol 355:245-256. (Pubitemid 28404707)
23. Nichols DE (2004) Hallucinogens. Pharmacol Ther 101:131-181.
24. Nonaka R, Nagai F, Ogata A, and Satoh K (2007) In vitro screening of psychoactive drugs by [(35)S]GTPγS binding in rat brain membranes. Biol Pharm Bull 30: 2328-2333. (Pubitemid 350223736)
25. Tomaszewski Z, Johnson MP, Huang X, and Nichols DE (1992) Benzofuran bioisosteres of hallucinogenic tryptamines. J Med Chem 35:2061-2064.
26. Winter JC (2009) Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines. Psychopharmacology 203:251-263.